List of Tyrvaya drug patents

Tyrvaya is owned by Oyster Point Pharma.

Tyrvaya contains Varenicline Tartrate.

Tyrvaya has a total of 6 drug patents out of which 0 drug patents have expired.

Tyrvaya was authorised for market use on 15 October, 2021.

Tyrvaya is available in solution;nasal dosage forms.

Tyrvaya can be used as treatment of the signs and symptoms of dry eye disease (ded).

The generics of Tyrvaya are possible to be released after 19 October, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224598 OYSTER POINT PHARMA Methods of increasing lacrimal proteins
Oct, 2035

(12 years from now)

US10456396 OYSTER POINT PHARMA Dry eye treatments
Oct, 2035

(12 years from now)

US9597284 OYSTER POINT PHARMA Dry eye treatments
Oct, 2035

(12 years from now)

US9532944 OYSTER POINT PHARMA Methods of improving ocular discomfort
Oct, 2035

(12 years from now)

US9504644 OYSTER POINT PHARMA Methods of increasing tear production
Oct, 2035

(12 years from now)

US9504645 OYSTER POINT PHARMA Pharmaceutical formulations for treating ocular conditions
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 15, 2024

Drugs and Companies using VARENICLINE TARTRATE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in